Abstracts tagged "Lupus nephritis"

Abstract Number: 0920 • ACR Convergence 2023
Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
Xing Lyu¹, minghui li¹, ping zhang², Wei Wei³, victoria werth⁴ and Ming-Lin Liu⁵, ¹Tianjin Medical University, Tianjin, China, ²Beaumont Hospital Royal Oak, Royal Oak, MI, ³Tianjin Medical University General Hospital, Tianjin, China, ⁴University of Pennsylvania, Wynnewood, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…
Abstract Number: 1481 • ACR Convergence 2023
Racial Disparities in Lupus Nephritis: A Nationwide Analysis
Faria Sami¹, Shahzad Ahmed Sami², Augustine Manadan³ and Shilpa Arora¹, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²Trinity Health Oakland Hospital, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Lupus nephritis (LN) is a significant predictor of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Racial disparities are known to exist in SLE…
Abstract Number: 1652 • ACR Convergence 2023
Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders
Melicent Miller¹, Stephanie Slan¹, Rosalind Ramsey-Goldman², Rodlescia Sneed³, Candace Feldman⁴, Patrick Wildman¹, Tori Justin⁵, Lydia Oberholtzer⁵ and Joy Buie⁶, ¹Lupus Foundation of America, Washington, DC, ²Northwestern University, Chicago, IL, ³Wayne State University, Detroit, MI, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Sharp Insight, LLC, Montgomery County, MD, ⁶Lupus Foundation of America, York, SC
Background/Purpose: Black/African American people with lupus (PWL) experience greater disease prevalence and severity than White PWL. The need for more racial and ethnic diversity amongst…
Abstract Number: 2336 • ACR Convergence 2023
Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis
David Jayne¹, Eduardo Mysler², Zahir Amoura³, Patrick Gavin⁴, Erik Allman⁴, Cristina Di Poto⁴, Xiang Tian⁴, Sonja Hess⁴, Eszter Csomor⁵, Philip Brohawn⁴, Daniel Muthas⁵, Adam Platt⁶, Hussein Al-Mossawi⁶, Catharina Lindholm⁵ and Nicola Ferrari⁶, ¹University of Cambridge, Cambridge, United Kingdom, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, ⁴BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
Abstract Number: 0781 • ACR Convergence 2023
Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials
Amit Saxena¹, Peter Izmirly², Jammie Law³, Cristina Sorrento³, H Michael Belmont⁴ and Jill Buyon⁵, ¹New York University Grossman School of Medicine, Rheumatology, New York, NY, ²New York University School of Medicine, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵NYU Grossman School of Medicine, New York, NY
Background/Purpose: Traditional induction treatment regimens for proliferative or membranous lupus nephritis (LN) have utilized oral glucocorticoids (GC) in initial doses up to 1.0 mg/kg/day prednisone…
Abstract Number: 0921 • ACR Convergence 2023
SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis
Yevgeniya Gartshteyn¹, Leila Khalili², Laura Geraldino-Pardilla², Adam Mor³ and Anca Askanase⁴, ¹Columbia University Medical Center, New York, NJ, ²Division of Rheumatology, Columbia University Irving Medical Center, New York, NY, ³Columbia University, New York, NY, ⁴Columbia University Medical Center, New York, NY
Background/Purpose: Better understanding of the abnormal immune responses in lupus nephritis (LN) is fundamental to identifying new therapies. We previously reported that the adaptor protein…
Abstract Number: 1482 • ACR Convergence 2023
Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan
Takehiro Nakai¹, Sho Fukui², Takahiro Asano¹, Futoshi Iwata¹, Hiroki Ozawa³, Satoshi Kawaai¹, Yukihiko Ikeda⁴, Haruyuki Yanaoka¹, Hiromichi Tamaki¹, Mitsumasa Kishimoto⁵, Kenichi YAMAGUCHI⁶ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Brigham and Women's Hospital, Boston, MA, ³Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, ⁴St Luke's international hospital in Japan, Tokyo, Japan, ⁵Kyorin University School of Medicine, Yokohoma, Japan, ⁶St.Luke's International Hospital, Tokyo, Japan
Background/Purpose: Over the past several decades, the treatment of lupus has seen significant advancements, with the approval of belimumab in 2017, and anifrolumab in 2021.…
Abstract Number: 1693 • ACR Convergence 2023
Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Alice Horisberger¹, Alec Griffith¹, Arnon Arazi², Joshua Keegan¹, Kaitlyn Howard¹, Takanori Sasaki¹, Tusharkanti Ghosh³, Andrea Fava⁴, Jun Inamo⁵, John Pulford¹, Ekaterina Murzin¹, Brandon Hancock¹, Katie Preisinger⁶, Maria Gutierrez-Arcelus⁷, Thomas Eisenhaure⁸, Joel Guthridge⁹, Paul Hoover¹⁰, Maria Dall'Era¹¹, David Wofsy¹¹, Diane L. Kamen¹², Kenneth Kalunian¹³, Richard Furie¹⁴, H Michael Belmont¹⁵, Peter Izmirly⁶, Robert Clancy¹⁶, David Hildeman¹⁷, steve Woodle¹⁷, William Apruzzese¹⁸, Maureen McMahon¹⁹, Jennifer Grossman²⁰, Jennifer Barnas²¹, Fernanda Payan-Schober²², Mariko Ishimori²³, Accelerating Medicines Partnership Program RA SLE Network²³, Matthias Kretzler²⁴, Celine Berthier²⁴, Jeff Hodgin²⁴, Dawit Demeke²⁴, Chaim Putterman²⁵, Nir Hacohen⁸, Michael Brenner¹, Jennifer Anolik²¹, Anne Davidson²⁶, Judith James⁹, Soumya Raychaudhuri¹⁰, Michelle Petri²⁷, Jill Buyon¹⁶, Betty Diamond²⁶, The Accelerating Medicines Partnership In RA/SLE²⁸, Fan Zhang²⁹, James Lederer¹ and Deepak Rao¹⁰, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Broad Institute of MIT and Harvard, Melrose, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴Johns Hopkins University, Baltimore, MD, ⁵University of Colorado School of Medicine, Aurora, CO, ⁶New York University School of Medicine, New York, NY, ⁷Boston Children's Hospital, Boston, MA, ⁸Broad Institute of MIT and Harvard, Cambridge, MA, ⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁰Brigham and Women's Hospital, Boston, MA, ¹¹University of California San Francisco, San Francisco, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³University of California San Diego, La Jolla, CA, ¹⁴Northwell Health, Manhasset, NY, ¹⁵NYU School of Medicine, New York, NY, ¹⁶NYU Grossman School of Medicine, New York, NY, ¹⁷University of Cincinnati College of Medicine, Cincinnati, OH, ¹⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ¹⁹UCLA David Geffen School of Medicine, Los Angeles, CA, ²⁰University of California Los Angeles, Los Angeles, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Texas Tech University Health Sciences Center, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴University of Michigan, Ann Arbor, MI, ²⁵Albert Einstein College of Medicine, Bronx, NY, ²⁶Feinstein Institutes for Medical Research, Manhasset, NY, ²⁷Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁸multisites, multisites, ²⁹University of Colorado, Aurora, CO
Background/Purpose: Patients with lupus nephritis (LN) have variable responses to standard-of-care therapy, and a third of patients with class III, IV, or V show a…
Abstract Number: 2338 • ACR Convergence 2023
Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis
Maria Dall'Era¹, Juan Lichauco², Hsiang Chen³, Harold Gomez⁴, Michael Tee⁵, Caroline Arroyo⁶, Joung-Liang Lan⁷, Yao-Fan Fang⁸, Edmund Chang⁹, Noosha Yousefpour⁹, Julian Low⁹, Min Bao⁹, Qing Chang⁹, Jeannette Osterloh⁹, Ann Mongan⁹, Ted Yednock⁹, Dean Artis⁹, Yaisa Andrews-Zwilling⁹ and Henk-Andre Kroon⁹, ¹University of California San Francisco, San Francisco, CA, ²St. Luke’s Medical Center, Quezon City, Philippines, ³Tri-service General Hospital, Taipei City, Taiwan, ⁴Angeles University Foundation Medical Center, Pampanga, Philippines, ⁵Medical Center Manila and University of the Philippines Manila, Manila, Philippines, ⁶Iloilo Doctors Hospital, Iloilo City, Philippines, ⁷China Medical University Hospital, Taichung, Taiwan, ⁸Chang Gung Memorial Hospital, Linkou, Taiwan, ⁹Annexon Biosciences, Brisbane, CA
Background/Purpose: Lupus nephritis (LN) is an autoantibody-mediated disease involving glomerular deposition of immune complexes containing pathogenic anti-C1q antibodies, leading to C1q binding and activation of…
Abstract Number: 0782 • ACR Convergence 2023
Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies
Maria Dall'Era¹, Ernie Yap², Matt Truman², Lucy Hodge² and Neil Solomons³, ¹University of California San Francisco, San Francisco, CA, ²Aurinia Pharmaceuticals Inc., Edmonton, AB, Canada, ³Neil Solomons Consulting Inc., Victoria, BC, Canada
Background/Purpose: Dual-immunosuppressive regimens consisting of high-dose glucocorticoids and higher doses ( >2 g/day) of mycophenolate mofetil (MMF) are still frequently used for the initial management…
Abstract Number: 0922 • ACR Convergence 2023
The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles
Tomás Cerdó¹, Carlos Perez-Sanchez², Laurel Woodridge³, Mª Angeles Aguirre⁴, Rafaela Ortega Castro⁵, Ismael Sánchez-Pareja⁶, Laura Muñoz-Barrera¹, Pedro Segui¹, Christian Merlo⁶, Pedro Ortiz Buitrago⁷, Desiree Ruiz Vilchez⁸, Maria del Carmen Abalos-Aguilera⁸, Pilar Font Ugalde¹, Nuria Barbarroja⁹, Alejandro Escudero¹⁰, Elizabeth Jury³ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁵Hospital Reina Sofía, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁹University of Cordoba, Córdoba, Spain, ¹⁰SAS, Córdoba, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) poses a significant challenge at the diagnostic and treatment levels due to its severe multisystem nature and notable heterogeneity in…
Abstract Number: 1483 • ACR Convergence 2023
High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study
Shiori Nakagawa, Yasunori Iwata, Takahiro Yuasa, Keisuke Sako, Keisuke Horikoshi, Taichiro Minami, Megumi Oshima, Tadashi Toyama, Shinji Kitajima, Akinori Hara, Norihiko Sakai, Miho Shimizu and Takashi Wada, Department of Nephrology, Kanazawa University Hospital, Kanazawa, Japan
Background/Purpose: Lupus nephritis (LN) is a major manifestation which develops in more than 50% of patients with systemic lupus erythematosus (SLE), and is also a…
Abstract Number: 1695 • ACR Convergence 2023
Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis
Philip Carlucci¹, Jasmine Shwetar², Siddarth Gurajala³, Qian Xiao³, Joseph Mears⁴, Katie Preisinger¹, Devyn Zaminski⁵, Kristina Deonaraine¹, Peter Izmirly¹, Andrea Fava⁶, Judith James⁷, Joel Guthridge⁷, Brad Rovin⁸, Sethu Madhavan⁸, Wade DeJager⁷, David Wofsy⁹, Ming Wu², Chaim Putterman¹⁰, Deepak Rao¹¹, Betty Diamond¹², Derek Fine¹³, Jose Monroy-Trujillo¹³, Kristin Haag¹⁴, H Michael Belmont⁵, William Apruzzese¹¹, Anne Davidson¹², Fernanda Payan-Schober¹⁵, Richard Furie¹⁶, Paul Hoover¹¹, Celine Berthier¹⁷, Maria Dall'Era⁹, Kerry Cho¹⁸, Diane L. Kamen¹⁹, Kenneth Kalunian²⁰, Jennifer Anolik²¹, Arnon Arazi²², Soumya Raychaudhuri¹¹, Nir Hacohen²³, Michelle Petri²⁴, Robert Clancy²⁵, Kelly Ruggles², Jill Buyon²⁵ and The Accelerating Medicines Partnership in RA/SLE²⁶, ¹New York University School of Medicine, New York, NY, ²NYU Langone, New York, NY, ³Harvard Medical School, Boston, MA, ⁴Michigan University, Ann Arbor, MI, ⁵NYU School of Medicine, New York, NY, ⁶Johns Hopkins University, Baltimore, MD, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Ohio State University, Columbus, OH, ⁹University of California San Francisco, San Francisco, CA, ¹⁰Albert Einstein College of Medicine, Bronx, NY, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Feinstein Institutes for Medical Research, Manhasset, NY, ¹³Johns Hopkins School of Medicine, Baltimore, MD, ¹⁴Thomas Jefferson University, Philadelphia, PA, ¹⁵Texas Tech University Health Sciences Center, El Paso, TX, ¹⁶Northwell Health, Manhasset, NY, ¹⁷University of Michigan, Ann Arbor, MI, ¹⁸UCSF Health, San Francisco, CA, ¹⁹Medical University of South Carolina, Charleston, SC, ²⁰University of California San Diego, La Jolla, CA, ²¹University of Rochester Medical Center, Rochester, NY, ²²Broad Institute of MIT and Harvard, Melrose, MA, ²³Broad Institute of MIT and Harvard, Cambridge, MA, ²⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁵NYU Grossman School of Medicine, New York, NY, ²⁶Multiple, Bethesda, MD
Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
Abstract Number: 2340 • ACR Convergence 2023
Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Omer Pamuk¹, Bisma Shaikh², Saif Khan³, Ali Abbas⁴, Sarah Abi Doumeth⁵ and sarfaraz Hasni⁶, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²Jinnah Sindh Medical University, Karachi, Pakistan, ³College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴Alabama College of Osteopathic Medicine, Dothan, AL, ⁵Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁶Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
Abstract Number: 0784 • ACR Convergence 2023
Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial
Brad Rovin¹, Jorge Ross Terres², Sophia Giang³, Thomas Schindler⁴, Armando Turchetta⁵, Jay Garg², Richard Furie⁶, William F. Pendergraft III² and Ana Malvar⁷, ¹Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Genentech, Inc., San Francisco, CA, ⁴F. Hoffmann-La Roche Ltd, Basle, Switzerland, ⁵F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁶Northwell Health, Manhasset, NY, ⁷Hospital Fernandez, Buenos Aires, Argentina
Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…

« Previous Page
1
…
7
8
9
10
11
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].